Surgery before chemo and immunotherapy may boost lung cancer outcomes

NCT ID NCT07177105

Not yet recruiting Disease control Sponsor: Jianxing He Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether surgically removing the primary lung tumor before giving immunotherapy (sintilimab) and chemotherapy can improve outcomes for people with advanced non-small cell lung cancer that is not driven by EGFR or ALK mutations. About 118 participants will be randomly assigned to either receive surgery followed by the drug combination, or the drugs alone. The main goal is to see if the surgery helps delay cancer progression or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab, pemetrexed, carboplatin, and cytoreductive surgery
What this could lead to: If successful, this could show that removing the primary tumor before immunotherapy and chemotherapy helps people with advanced lung cancer live longer without their disease getting worse.
What could go wrong: This is a Phase 2 trial with only 118 participants, so results are preliminary. Surgery in advanced cancer carries risks like infection or complications, and the added benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.